Effect of intranasal IL-12 gene therapy on the mice eosinophils and IL-5 in the murine model of allergic rhinitis
10.3760/cma.j.issn.1673-0860.2009.06.013
- VernacularTitle:白介素12基因治疗对变应性鼻炎小鼠嗜酸粒细胞及白介素5的影响
- Author:
Hong-Rui ZANG
1
;
Tong WANG
;
Er-Zhong FAN
;
Ying LI
;
Bing ZHOU
Author Information
1. 首都医科大学附属北京同仁医院
- Keywords:
Rhinitis,allergic,perennial;
Gene therapy;
Interleukin-12;
Interleukin-5;
Eosinophilia;
Mice
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2009;44(6):499-503
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of intranasal liposome-mediated IL-12 gene therapy on the eosinophils and IL-5 in the murine model of allergic rhinitis. Methods Thirty-six BALB/C mice were randomly divided into allergic rhinitis (AR) group, gene therapy group and control group. Allergic rhinitis group were sensitized and stimulated by ovalbumin(OVA), and gene therapy group were administered with hposome-mediated pGEG. m IL-12 transnasally before stimulated. The eosinophiis in bone marrow were counted by Wright's staining, and the eosinophils in nasal mucosa were counted by HE staining. The eosinophils of peripheral blood were detected by flow cytometry. The expression of IL-5 in bone marrow and nasal mucosa was examined by immunohistochemistry. The IL-5 in serum was detected by ELISA. Results Among the three groups, the difference of all data was statistically significant (P<0.01). Multiple Comparison showed that the ratio of eosinophils to white cells and the mount of IL-5 positive cells in nasal mucosa and bone marrow of gene therapy group was significantly lower than that of AR group (P<0.05).The ratio of eosinophils to granulocyte(0.124±0.031) and the expression level of IL-5[(29. 51±6. 68) pg /ml]in peripheral blood [0.184±0. 079 and (56. 58±16. 80) pg/ml] were significantly lower in gene therapy group than in AR group (P<0.05). Conclusions Transnasal administration of liposome- mediated pGEG. mIL-12 could depress the expression of IL-5 in bone marrow, peripheral blood, and nasal mucosa, to influence the proliferation and differentiation of eosinophils and decrease the delivery and transference of eosinophils to peripheral blood and nasal mucosa. It may be a new treatment for respiratory tract allergic inflammation.
